Table 2.
Descriptive analysis for active versus inactive patients on July 28, 2008.
| Variable | Active (n=34) |
Inactive (n=66) |
Total |
|---|---|---|---|
| Gender | |||
| Male (%) | 23 (68%) | 47 (71%) | 70 (70%) |
| Female (%) | 11 (32%) | 19 (29%) | 30 (30%) |
| Ethnicity | |||
| African American (%)** | 14 (41%) | 14 (21%) | 37 (24.2%) |
| Latino (%)** | 10 (29%) | 33 (50%) | 62 (40.5%) |
| Caucasian (%) | 10 (29%) | 18 (27%) | 52 (34.0%) |
| Multi-racial (%) | 0 (0%) | 1 (2%) | 2 (1.3%) |
| Insured (%) | 30 (88%) | 53 (80%)++ | 83 (83%)+++ |
| Employed (%) | 17 (50%) | 30 (46%) | 47 (47%) |
| Route of administration | |||
| Injection (%) | 11 (32%) | 34 (52%) | 45 (45%) |
| Oral (%) | 6 (18%) | 7 (11%) | 13 (13%) |
| Inhale (%) | 17 (50%) | 25 (38%) | 42 (42%) |
| Drug used | |||
| Heroin (%) | 25 (74%) | 58 (88%) | 83 (83%) |
| Methadone (%) | 3 (9%) | 4 (6%) | 7 (7%) |
| Vicodin (%) | 5 (15%) | 4 (6%) | 9 (9%) |
| Mean Age applied Buprenorphine TX (S.D) | 43 (12.7) | 39.1 (12.1) | 40.5 (12.4) |
| Mean Age 1st misused opioid (S.D) | 22.1 (8.2) | 20.6 (7.4) | 21.1 (7.6) |
| Past MMTP (%) | 23 (68%) | 32 (49%) | 55 (55%) |
**
p<.05